Flunarizine Hydrochloride Tablets

This product is a calcium channel blocker. It can prevent cell damage caused by pathological calcium overload in cells due to ischemia and other reasons. This product has the following effects: 1. It relieves vasospasm and has a lasting inhibitory effect on persistent vasospasm caused by vasoconstrictor substances, especially on the basilar artery and internal carotid artery. Its effect is 15 times stronger than that of cerbrine; 2. It has vestibular inhibitory effect, which can increase the blood flow of cochlear arterioles and improve the circulation of vestibular organs; 3. It has anti-epileptic effect, which can block the pathological calcium overload of nerve cells and prevent paroxysmal depolarization and cell discharge, thereby avoiding epileptic seizures; 4. It protects the myocardium and significantly reduces ischemic myocardial damage; 5. Flunarizine also has the effect of improving renal function and can be used for chronic renal failure; in addition, this product also has anti-histamine effect.

The main ingredient of this product is flunarizine hydrochloride. The chemical name is: (E)-1-[bis(4-fluorophenyl)methyl]-4-2(2-propenyl-3-phenyl)-piperazine dihydrochloride. Its structural formula is: Molecular formula: C26H26F2N22HCl Molecular weight: 477.42

This product is white tablets.

1. Insufficient blood supply to the brain, vertebral artery ischemia, cerebral thrombosis, etc. 2. Tinnitus, dizziness. 3. Prevention of migraine. 4. Auxiliary treatment of epilepsy.

Oral administration: 6-12 mg (1-2 tablets each time), once a day, before bedtime.

1. Adverse reactions of the central nervous system include: ① Drowsiness and fatigue are the most common; ② Depression may occur in long-term users, which is more common in female patients; ③ Extrapyramidal symptoms, manifested as involuntary movements, mandibular movement disorders, rigidity, etc. Most of them appear after 3 weeks of medication and disappear after stopping the medication. It is more likely to occur in the elderly; ④ A small number of patients may experience insomnia, anxiety and other symptoms. 2. Gastrointestinal symptoms are manifested as: burning sensation in the stomach, hyperappetite, increased food intake, and weight gain. 3. Others: A small number of patients may experience symptoms such as rash, dry mouth, galactorrhea, muscle aches, etc. But most of them are transient and can be relieved by stopping the medication.

This drug is contraindicated in patients with a history of allergy to the drug, a history of depression, or acute cerebral hemorrhage.

Precautions for children: Since this drug can pass through the blood-brain barrier, it has clear adverse reactions in the central nervous system and the central nervous system of children is sensitive to the drug; the metabolic function is relatively weak. Although there is no detailed research data on the use of drugs in children, in principle, children should be cautious or prohibited from using this drug. Precautions for pregnancy and lactation: Since this drug can pass through the placental barrier and can be secreted with breast milk, although there are no reports of teratogenicity and effects on placental development, pregnant women and lactating women should not use this drug in principle. Precautions for the elderly: Since the nervous system of elderly patients is more sensitive and their metabolic capacity is weaker, the dosage should be reduced as appropriate.

1. When used in combination with alcohol, hypnotics or sedatives, the sedative effect is aggravated. 2. When used in combination with phenytoin sodium and carbamazepine, the blood concentration of flunarizine can be reduced. 3. When used in combination with cinnarizine in patients undergoing radiotherapy, it can increase the killing power of tumor cells. 4. Adding flunarizine to anti-epileptic drug treatment can improve the anti-epileptic effect.

Keep away from light and store in a sealed container.

5mg (based on C26H26F2N2)

24 months

Harbin Pharmaceutical Group Pharmaceutical Factory No.6

• Founded in:

  1994-05-20

• Address:

  No. 326, Nanzhi Road, Daowai District, Harbin, Xingye East Road, Limin Economic and Technological Development Zone, Harbin

• Tax NO.:

  912301001270449678

• Registered Funds:

  -

• Website:

  Log in to view

• Email:

  Log in to view